Article Text

other Versions

PDF
Response to: ‘When is it not ethical to withhold treatment for rheumatoid arthritis?’ by Dr Yusuf Yazici
  1. Tsutomu Takeuchi
  1. Correspondence to Professor Tsutomu Takeuchi, Division of Rheumatology, School of Medicine, Keio University, Shinanomachi 35, Shinjyuku, Tokyo 160-8582, Japan; tsutake{at}z5.keio.jp

Statistics from Altmetric.com

The ethical consideration in placebo-controlled studies of antirheumatic drugs is of primary importance. We thank Dr Yazici1 for his questions regarding the ethical aspect of our study.2

The GO-MONO study was designed to have placebo crossover to methotrexate (MTX) at week 16, as a Registration Study to Japan Health Authority, following the MHLW Guideline for the Clinical Study and Evaluation of Drugs for Rheumatoid Arthritis (RA), which is similar to the US Food and Drug Administration's Guidance for Industry RA.3 The US guidance recommends sponsors to limit the use of placebo as a control and consider the use of an active comparator as the control, or the escape to rescue treatment in studies longer than 12 weeks. In the event …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles